Aclaris Therapeutics (ACRS) Change in Accured Expenses (2014 - 2026)

Aclaris Therapeutics' Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$3.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 72.6% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at -$81000.0 (up 96.1% YoY), while the FY2025 annual figure was -$8.1 million, down 105.4% from the prior year.
• Change in Accured Expenses was -$3.0 million for Q1 2026 at Aclaris Therapeutics, down from $1.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $11.6 million in Q4 2024 to a low of -$12.9 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$146000.0 across 5 years, with a median of $399000.0 in 2025.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 928.49% in 2023, then slumped 1012.67% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$681000.0 in 2022, then soared by 928.49% to $5.6 million in 2023, then soared by 105.1% to $11.6 million in 2024, then tumbled by 89.19% to $1.3 million in 2025, then tumbled by 341.89% to -$3.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.0 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.